Supplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E,

Similar documents
Supplementary Figure 1 Weight and body temperature of ferrets inoculated with

Relative activity (%) SC35M

modified dye uptake assay including formazan test EC 90 not tested plaque reduction assay

Supplementary Figure 1 Schematic overview of the mutant virus libraries and their

To test the possible source of the HBV infection outside the study family, we searched the Genbank

Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication

HCV NS3 Protease Drug Resistance

A Comprehensive Study of TP53 Mutations in Chronic Lymphocytic Leukemia: Analysis of 1,287 Diagnostic CLL Samples

HCV NS3 Protease Drug Resistance

Supplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid.

Deep-Sequencing of HIV-1

Update on Zoonotic Infections with Variant Influenza A Viruses in the USA

SUPPLEMENTAL MATERIAL

Supplementary Figure 1

Study Design - GT 1 Retreatment

Transmission of integrase resistance HIV

Vertical Magnetic Separation of Circulating Tumor Cells and Somatic Genomic-Alteration Analysis in Lung Cancer Patients

screening procedures Disease resistant to full-dose imatinib ( 600 mg/day) or intolerant to any dose of imatinib

CHAPTER 8 ONCOGENIC MARKER DETECTION FROM P53 MUTANT AMINO-ACID SUBSTITUTIONS

FIG S1 Examination of eif4b expression after virus infection. (A) A549 cells

LAL: significato clinico e biologico delle mutazioni di Bcr-Abl

HIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe

IS MUTATION ANALYSIS OF BCR-ABL OF ANY VALUE IN CLINICAL MANAGEMENT OF CML PATIENTS? David Marin, Imperial College London

Nature Medicine: doi: /nm.4322

ULTRA-DEEP SEQUENCING OF THE BCR-ABL KINASE DOMAIN FOR BETTER THERAPEUTIC TAILORING OF PHILADELPHIA CHROMOSOME-POSITIVE LEUKEMIA PATIENTS

CPTR title slide. A Standardized System for Grading Mutations in Mycobacterium tuberculosis for Association with Drug Resistance

Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis

Influenza antiviral susceptibility: methods and challenges to detect resistant virus

Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine

Clinical Applications of Resistance Stuart C. Ray, MD

SUPPLEMENTARY INFORMATION

Supplementary Figure 1. Prevalence of U539C and G540A nucleotide and E172K amino acid substitutions among H9N2 viruses. Full-length H9N2 NS

Sample Metrics. Allele Frequency (%) Read Depth Ploidy. Gene CDS Effect Protein Effect. LN Metastasis Tumor Purity Computational Pathology 80% 60%

172R 172K TAM-2/172R TAM-2/172K. AZT concentration [nm] AZT concentration [nm] MgCl 2 2.5K 2.5K 5K 2.5K 5K 2.5K K 5K 2.5K 5K 2.5K 50 2.

Received 21 November 2005/Returned for modification 20 January 2006/Accepted 27 March 2006

The role of E148Q in FMF. Elon Pras Institute of Human Genetics Sheba Medical Center

History (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11

Supplemental Table 1. The list of variants with their respective scores for each variant classifier Gene DNA Protein Align-GVGD Polyphen-2 CADD MAPP

Resistance of Human Cytomegalovirus to Antiviral Drugs

Resistance Workshop. 3rd European HIV Drug

Multifunctional Adaptive NS1 Mutations Are Selected upon Human Influenza Virus Evolution in the Mouse

CML Treatment Failure: More Threatening Than It Appears. Mutation Testing

SUPPLEMENTARY INFORMATION. Rare independent mutations in renal salt handling genes contribute to blood pressure variation

Changing demographics of smoking and its effects during therapy

NEXT GENERATION SEQUENCING OPENS NEW VIEWS ON VIRUS EVOLUTION AND EPIDEMIOLOGY. 16th International WAVLD symposium, 10th OIE Seminar

Genetic Analysis of Allosteric Signaling in RhaR from Escherichia coli and Characterization of the VirF Protein from Shigella flexneri

SUPPLEMENTARY INFORMATION

Impact of Amino Acid Mutations in PB2, PB1-F2, and NS1 on the Replication and Pathogenicity of Pandemic (H1N1) 2009 Influenza Viruses

New drugs and trials. Andreas Hochhaus

Resistance to Integrase Strand Transfer Inhibitors

33VASTVNGATSANNHGEPPS51PADARPR58

SESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy

ICAAC/IDSA DC, Oct. 26, 2008

Influenza A Virus Transmission Bottlenecks Are Defined by Infection Route and Recipient Host

New technologies reaching the clinic

Ubiquitination and deubiquitination of NP protein regulates influenza A virus RNA replication

WHO NIC at Research Institute of Influenza and D.I. Ivanovsky Institute of Virology INTEGRATED DATA OF INFLUENZA MORBIDITY AND DIAGNOSIS

C-CREST study, Part A: GZR + EBR or MK MK-3682 for genotypes 1, 2 and 3 - Phase II

Dedicated to Preventing and Treating Life-Threatening Viral Infections. Randall Lanier Vice President, Biology

Susanne Schnittger. Workflow of molecular investigations in JAK2-negative MPNs - the Munich experience

Personalized Healthcare Update

Resistencias & Epidemiología. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña

ph1n1 H3N2: A Novel Influenza Virus Reassortment

Influenza virus exploits tunneling nanotubes for cell-to-cell spread

Genotyping and Drug Resistance in Clinical Practice. Case Studies

Animal hosts Natural host Laboratory animals Rabbits Mice Rats Hamsters Newborn or suckling rodents Animal models for viral pathogenesis 4 Growth of v

SUPPLEMENTARY INFORMATION

Update on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School

From Mosquitos to Humans: Genetic evolution of Zika Virus

Distinct Mutation Pathways of Non-Subtype B HIV-1 during In Vitro Resistance Selection with Non-Nucleoside Reverse Transcriptase Inhibitors

Kalydeco. Kalydeco (ivacaftor) Description

Introduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School

Evaluation and Management of Virologic Failure

Supporting Information

Original Article Development and Sequence Analysis of a Cold-Adapted Strain of Influenza A/New Caledonia/20/1999(H1N1) Virus

Fabry Disease X-linked genetic, multi-organ disorder. Fabry disease screening program in Hypertrophic p Cardiomyopathy: preliminary results.

NNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER

Nature Immunology: doi: /ni Supplementary Figure 1. Production of cytokines and chemokines after vaginal HSV-2 infection.

Supplementary Information. Induction of p53-independent apoptosis by ectopic expression of HOXA5

Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses

Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V

What do we need to know about RAVs clinically?

Update on HIV-1 Drug Resistance and Tropism Testing

J. A. Mayfield et al. FIGURE S1. Methionine Salvage. Methylthioadenosine. Methionine. AdoMet. Folate Biosynthesis. Methylation SAH.

Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R

TECHNICAL DOCUMENT Community Network of Reference Laboratories (CNRL) for Human Influenza in Europe

Differential Localization and Function of PB1-F2 Derived from Different Strains of Influenza A Virus

Flu, Avian Flu and emerging aspects (H1N1 resistance)

The Infectious Cycle. Lecture 2 Biology W3310/4310 Virology Spring You know my methods, Watson --SIR ARTHUR CONAN DOYLE

Hepatitis C Resistance Associated Variants (RAVs)

Infect MCF-7 cells carrying dcas9-vp64 + psm2-p65-hsf1 with SAM library or vector. Introduce AKT reporter

Supplementary Figure 1. Antibiotic partially rescues mice from sepsis. (ab) BALB/c mice under CLP were treated with antibiotic or PBS.

Ali Alabbadi. Bann. Bann. Dr. Belal

Form 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data

Supplementary material for the manuscript

Nature Genetics: doi: /ng Supplementary Figure 1. Details of sequencing analysis.

Update on new agents in Gastrointestinal Tumor (GIST)

ARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za

days days and gbt-i.cd Recipient 20

I m B m. 1 f ub I B. D m B. f u. 1 f ua 1 D I A. I A m. D m A. f a. 1 f u. D m B ) D m A )(I m B. 1 f ua. 1 (I m A. log (I A. log f.

Transcription:

Supplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E, TY93/H5N1 GFP-627K, or the TY93/H5N1 PB2(588-759) virus library. To establish our GFP- FACS screening platform, we compared the GFP expression levels of TY93/H5N1 GFP-627E (a) and TY93/H5N1 GFP-627K (b) viruses 5 h after infection of 10 6 293 cells at an MOI of 0.1. For mutant virus library screens, cells were infected with control TY93/H5N1 GFP-627E virus (c), or with one of the mutant virus libraries; shown here is the result for TY93/H5N1 PB2(588 759) (d). Approximately 100,000 cells were analyzed per virus or virus library.

Supplementary Figure 2. Growth kinetics of mutant TY93/H5N1 viruses in 293 and Calu-3 cells. Human 293 (a) or Calu-3 (b) cells were infected with virus at an MOI of 0.01 and incubated at 33 C or 37 C. At the indicated time points post-infection, virus titers were determined by use of plaque assays in MDCK cells. Values shown are the means (± standard deviation) of three separate infections.

Mutation Frequency T 598S + A684S 1 L607Q 2 D611A 1 D611A + L618M 1 611D/N 1 1 D611G 3 D611G + E627V 1 D611N 3 V613A + E627V 2 L618M 2 A624S 2 E627K 7 E627K + R630I 1 627E/K 1 2 E627V 33 627E/V 1 8 I647L 5 Y658S 1 T 676S 1 A684S 1 V686M + D701V 1 V690I 1 K702R 1 D740N 2 I758T 2 Wild-type 11 1 Mixed population: Listed are the wild-type and mutant amino s at their respective positions. Supplementary Table 1. Mutations in PB2 isolated from the pilot screen of the TY93/H5N1 PB2(588 759) library.

Sample 1* 2 I185T 100 3 T 21I 45 4 Y488C 20 5** 6* 7* 8 9** 10** 11 12* 13* 14 15* I64V 30 F404L 21 N425K 50 M467L 55 S334C 57 L384S 50 F404L 40 G74E 35 E192K 65 E69D 63 T 105A 65 T 178A 66 16 D195E 63 17 18* 19** 20** PB2 E158G 98 A674E 98 Q138L 40 C196F 47 *Contains one or more synonomous substitutions in the NP and/or polymerase genes. **No mutations in the polymerase or NP genes. Supplementary Table 2. Deep-sequencing analysis of the polymerase and NP genes of viruses isolated from the TY93/H5N1 PB2(1 587) mutant virus library.

Sample PB2 PB1 PA NP 1 E627K 78 2 E627K 96 N473K 35 3 E627V 97 N473K 34 4 E627V 96 K718R 86 5* E627V 97 R269I 26 6* Q591K 90 7* V584I 98 A622V 97 E627K 96 8* I647L 96 9* R175I 21 D701N 93 A260T 35 E191K 41 E627K 55 10* I647L 44 S653T 51 A689S 54 11* R101M 38 E627K 96 E627V 61 T637A 61 12* T683I 25 V14G 39 K578T 35 D701N 22 13* V613A 98 L708M 98 14* E627V 98 15* D611G 98 E627V 96 16* E627K 98 17* I647L 19 E627K 38 18* E627V 38 V667A 34 19 D701V 98 L708M 99 R468K 43 E627K 43 20* D701V 26 P706A 44 T609S 46 M631 44 21* T662A 45 N715Y 48 T676A 50 S709C 50 22 E627V 99 N759Y 98 23 E627K 98 24* V667I 99 25* E627V 99 T608A 32 E627K 99 26* F610I 25 I758T 72 27* D701N 97 28* E627K 98 E192G 100 29* E627K 98 30 E627K 98 Y658F 99 *Contains one or more synonomous substitutions in the NP and/or polymerase genes. Supplementary Table 3. Deep-sequencing analysis of the polymerase and NP genes of viruses isolated from the TY93/H5N1 PB2(588 759) mutant virus library.

PB1 PA NP Sample P13L 18 1* A139V 25 S152T 62 M688V 97 2 I376N 30 3* S84N 25 4 N105S 90 N145D 96 5 T 156I 41 6 V43F 50 7** 8 V273I 90 9* T 132I 72 I63M 28 E297G 24 E80K 30 10 N375D 91 T 34K 25 11* P64H 29 L683I 24 M171V 29 12* N694K 30 13* N473K 30 14* 15* 16* 17* 18* 19** 20** *Contains one or more synonomous substitutions in the NP and/or polymerase genes. **No mutations in the polymerase or NP genes. Supplementary Table 4. Deep-sequencing analysis of the polymerase and NP genes of viruses isolated from the TY93/H5N1 PB1 mutant virus library.

PA PB2 NP Sample 1 A178T 60 2* S652H 30 3* T 97I 98 S601Y 85 4* N473K 30 5* F35V 31 6 A598V 21 P83L 73 L686Q 30 7* N473K 31 8* T 608A 25 9* S588T 25 A156V 88 10 K626E 27 V122A 66 N473K 30 N675I 41 11 L72M 40 12* L655P 40 N473K 31 T 97I 87 13* Y232C 85 F612I 30 S648N 30 14 A156T 33 15* 16* 17** 18* 19** 20** *Contains one or more synonomous substitutions in the NP and/or polymerase genes. **No mutations in the polymerase or NP genes. Supplementary Table 5. Deep-sequencing analysis of the polymerase and NP genes of viruses isolated from the TY93/H5N1 PA mutant virus library.

Virus MLD 50 (PFU) Median survival time (days) 10 5 PFU 10 4 PFU 10 3 PFU 10 2 PFU 10 1 PFU 1 PFU Wild-type 178 9 9 10 - - PA-I97I 17.8 7* 8 10 11 - - PB1-N105S <1 5* 7* 8* 10* 13* 14* PB2-E192K <10 6* 8* 9* 9* 11* 10 PB2-Q591K 18 6* 7* 8* 9* - - PB2-E627K 18 5* 6* 7* 8* - - PB2-E627V 18 5* 6* 8* 8* 14* - PB2-D701N 3.2 5* 7* 7* 7* 9* - PB2D-701V 3.2 5* 6* 6* 7* 8* - PB2-K702R 25 7 10 12 14 13 - PB2-D740N 436 9-12 - - - PB2-I758T 31 8 8 10 11 - - *P <0.05 Log-Rank (Mantel-Cox) test Supplementary Table 6. MLD 50 values and median survival times of mice infected with wild-type or mutant TY93/H5N1 viruses. Initial M-RT-PCR Reaction Primer name Primer Sequence MBTUni12 ACGCGTGATCAGCAAAAGCAGG MBTUni12G ACGCGTGATCAGCGAAAGCAGG MBTUni13 ACGCGTGATCAGTAGAAACAAGG Primers used for Nested PCR Primer name Primer Sequence MBTUni12-PB2 ACGCGTGATCAGCRAAAGCAGGTCAA 1632R CATTGATGACGAATATGTTA 711F ATTGAAGTACTGCATTTGAC MBTUni13-PB2 ACGCGTGATCAGTAGAAACAAGGTCG MBTUni12-PB1 ACGCGTGATCAGCRAAAGCARGCAAA 1483R TCCGATTTATGTAAGACTTC 880F TGAGGAAGATGATGACTAAC MBTUni13-PB1 ACGCGTGATCAGTAGAAACARGGCA MBTUni12-PA ACGCGTGATCAGCRAAAGCAGGTACTG 1413R CACTCCCTTCATTATGTATT 863F GAAGTTCTTACTGATGGATG MBTUni13-PA ACGCGTGATCAGTAGAAACAAGGTACY MBTUni12-NP ACGCGTGATCAGCRAAAGCAGGGTWG MBTUni13-NP ACGCGTGATCAGTAGAAACAAGGGTAT Supplementary Table 7. Sequences of primers used for deep sequencing.